Vir Bio licenses CHD combo to Norgine for EUR 55M upfront, up to EUR 495M milestones; cash runway extended to Q4 2027

Vir Biotechnology, Inc.

Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.
Vir receives EUR 55M upfront, up to EUR 495M in milestones, plus tiered mid-teen to high-twenties % royalties.
Norgine to cover ~25% of go-forward external costs for ECLIPSE registrational program.
SOLSTICE Phase 2 data: 66% of CHD patients achieved HDV RNA target not detected at 48 weeks; well-tolerated.
Vir expects current cash, equivalents, and investments to extend into Q4 2027 under current operating plan.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vir Biotechnology, Inc. entered into License Agreement with Norgine Pharma UK Limited valued at EUR 55 million (effective 2025-12-16).

Action: entry
Agreement: license
Counterparty: Norgine Pharma UK Limited
Value: EUR 55 million
Effective: 2025-12-16

Exact text from the filing

On December 16, 2025, Vir Biotechnology, Inc. (Vir Bio) and Norgine Pharma UK Limited (together with its affiliates in the Norgine group of companies, Norgine) entered into a License Agreement (the Agreement) with respect to certain commercial rights to the combination of tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta (CHD).

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-057394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.